CareRx Croissance future
Future contrôle des critères 0/6
Les bénéfices de CareRx devraient diminuer de 54.6% par an tandis que son chiffre d'affaires annuel devrait croître de 4% par an. Le BPA devrait croître de en baisse de 12.5% par an.
Informations clés
-54.6%
Taux de croissance des bénéfices
-12.51%
Taux de croissance du BPA
| Consumer Retailing croissance des bénéfices | 5.7% |
| Taux de croissance des recettes | 4.0% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 11 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Jun 01
CRRX: Share Repurchases And Higher Future P/E Will Support Upside Potential
Narrative Update on CareRx The average analyst price target for CareRx has shifted from CA$5.38 to CA$5.14. Analysts point to updated fair value estimates, a slightly higher discount rate, more cautious revenue growth assumptions, lower projected profit margins, and a higher future P/E multiple as key drivers of the change.
Mise à jour du récit • May 04
CRRX: Completed Buyback And Stable Assumptions Will Support Long Term Upside
Analysts have nudged their CareRx price target slightly higher to CA$4.50, reflecting modest adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations. What's in the News CareRx completed a share repurchase of 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Mise à jour du récit • Apr 19
CRRX: Share Repurchase And Steady Assumptions Will Support Long Term Upside
Analysts have made slight adjustments to their CareRx price targets, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Their fair value estimate remains steady at CA$4.50.Mise à jour du récit • Apr 05
CRRX: Share Repurchase And Margin Outlook Will Support Long Term Upside
Analysts have modestly revised their CareRx price target to CA$4.50, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E, which keep the fair value estimate steady at CA$4.50. What's in the News CareRx completed a share repurchase of 246,069 shares, representing 0.39% of its shares, for a total of CA$0.49 million under the buyback announced on September 15, 2025 (Key Developments).Mise à jour du récit • Mar 22
CRRX: Share Repurchases And Higher Assumed P/E Will Support Future Upside
Analysts have adjusted their CA$ fair value estimate for CareRx from about CA$5.08 to roughly CA$5.38, reflecting updated views on revenue growth, profit margins, and future P/E assumptions. What's in the News CareRx completed a share repurchase program, buying back 246,069 shares between October 1, 2025 and March 4, 2026, equal to 0.39% of its shares, for a total of CA$0.49 million (Key Developments).Mise à jour du récit • Mar 07
CRRX: Improved Profit Outlook And Lower P/E Will Support Future Upside
Analysts have adjusted their CareRx price target slightly higher to CA$5.08 from CA$4.92, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: CA$5.08, up slightly from CA$4.92.Mise à jour du récit • Feb 21
CRRX: Lower Future P/E Will Support Stronger Shareholder Returns
Analysts have trimmed their target price on CareRx to CA$4.92. They link this move to slightly higher discount rate assumptions and a modestly lower revenue growth outlook, partially balanced by a small improvement in expected profit margins and a lower future P/E estimate.Mise à jour du récit • Feb 06
CRRX: Refined Earnings Assumptions Will Support Stronger Long Term Upside Potential
Analysts have slightly adjusted their price target on CareRx, citing updated assumptions around revenue growth, profit margins, discount rate and future P/E that fine tune rather than overhaul their previous fair value view. Valuation Changes Fair Value: Unchanged at 4.5x, indicating no shift in the overall valuation anchor used in the model.Mise à jour du récit • Jan 23
CRRX: Future Earnings Power Will Support Refined Fair Value Upside
Analysts have slightly adjusted their price target on CareRx, reflecting modest tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. Together these changes point to a more refined view of the company’s fair value around $4.50.Mise à jour du récit • Jan 09
CRRX: Future Earnings Power Will Drive Repriced Market Expectation
The analyst price target for CareRx has shifted from US$2.25 to US$4.50, with analysts attributing this change to updated assumptions about revenue growth, profitability, and future P/E. What's in the News Between September 15, 2025 and September 30, 2025, CareRx reported no share repurchases under its existing buyback program, with 0 shares repurchased for CAD 0 million in that period (Key Developments).Mise à jour du récit • Dec 24
CRRX: Higher Future Earnings Multiple Will Drive Stronger Shareholder Returns
Analysts have nudged their price target for CareRx slightly higher, raising it by about $0.06 per share. This reflects modestly stronger expectations for revenue growth and valuation multiples, despite a more cautious view on profit margins.Mise à jour du récit • Dec 10
CRRX: Upcoming Share Buybacks Will Support Stronger Future Shareholder Returns
Narrative Update on CareRx Analysts have modestly increased their price target on CareRx to reflect a slightly higher valuation multiple and stable expectations for revenue growth and profit margins. This translates into a small upward adjustment in projected equity value by a few cents per share.Mise à jour du récit • Nov 26
CRRX: Share Repurchase Program Will Drive Stronger Performance Ahead
Analysts have raised their price target for CareRx, increasing the fair value estimate from $4.00 to $4.86. This change reflects improved revenue growth expectations and a more favorable profit margin outlook.Article d’analyse • Sep 11
Is CareRx (TSE:CRRX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Nouveau récit • Apr 07
North Burnaby Fulfillment Center And European Automation Will Improve Operations
Debt restructuring and cost-saving measures likely increase net margins and improve earnings by reducing interest expenses and operational costs.Article d’analyse • Feb 11
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.4x right now...Article d’analyse • Oct 03
CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Article d’analyse • Aug 11
Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report
Last week, you might have seen that CareRx Corporation ( TSE:CRRX ) released its quarterly result to the market. The...Article d’analyse • Apr 22
Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Article d’analyse • Mar 17
Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher
CareRx Corporation ( TSE:CRRX ) shares have continued their recent momentum with a 28% gain in the last month alone...Article d’analyse • Oct 19
CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Article d’analyse • Aug 22
What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S
It's not a stretch to say that CareRx Corporation's ( TSE:CRRX ) price-to-sales (or "P/S") ratio of 0.3x right now...Article d’analyse • Sep 22
CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • May 14
These 4 Measures Indicate That CareRx (TSE:CRRX) Is Using Debt Extensively
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 415 | 8 | 30 | N/A | 3 |
| 12/31/2027 | 406 | 8 | 26 | N/A | 6 |
| 12/31/2026 | 385 | 6 | 16 | 33 | 7 |
| 3/31/2026 | 375 | 27 | 22 | 30 | N/A |
| 12/31/2025 | 370 | 26 | 23 | 31 | N/A |
| 9/30/2025 | 366 | 0 | 21 | 30 | N/A |
| 6/30/2025 | 366 | -2 | 23 | 32 | N/A |
| 3/31/2025 | 367 | -4 | 28 | 36 | N/A |
| 12/31/2024 | 367 | -5 | 30 | 38 | N/A |
| 9/30/2024 | 366 | -6 | 31 | 38 | N/A |
| 6/30/2024 | 367 | -7 | 27 | 34 | N/A |
| 3/31/2024 | 369 | -4 | 23 | 32 | N/A |
| 12/31/2023 | 371 | -5 | 19 | 27 | N/A |
| 9/30/2023 | 374 | -6 | 25 | 33 | N/A |
| 6/30/2023 | 378 | -7 | 30 | 38 | N/A |
| 3/31/2023 | 380 | -34 | 16 | 29 | N/A |
| 12/31/2022 | 382 | -34 | 9 | 22 | N/A |
| 9/30/2022 | 384 | -34 | -4 | 11 | N/A |
| 6/30/2022 | 358 | -36 | -5 | 10 | N/A |
| 3/31/2022 | 311 | -20 | -1 | 8 | N/A |
| 12/31/2021 | 263 | -23 | 0 | 7 | N/A |
| 9/30/2021 | 212 | -21 | 2 | 7 | N/A |
| 6/30/2021 | 187 | -24 | -6 | -3 | N/A |
| 3/31/2021 | 177 | -29 | -2 | 0 | N/A |
| 12/31/2020 | 162 | -18 | -2 | 0 | N/A |
| 9/30/2020 | 148 | -50 | -3 | -1 | N/A |
| 6/30/2020 | 134 | -47 | -2 | 0 | N/A |
| 3/31/2020 | 126 | -34 | -1 | 2 | N/A |
| 12/31/2019 | 125 | -46 | N/A | 6 | N/A |
| 9/30/2019 | 122 | -19 | N/A | 3 | N/A |
| 6/30/2019 | 119 | -20 | N/A | 4 | N/A |
| 3/31/2019 | 117 | -39 | N/A | 9 | N/A |
| 12/31/2018 | 119 | -35 | N/A | 7 | N/A |
| 9/30/2018 | 85 | -27 | N/A | 14 | N/A |
| 6/30/2018 | 97 | -23 | N/A | 12 | N/A |
| 3/31/2018 | 110 | -3 | N/A | 15 | N/A |
| 12/31/2017 | 122 | -4 | N/A | 16 | N/A |
| 9/30/2017 | 168 | -6 | N/A | 14 | N/A |
| 6/30/2017 | 170 | -3 | N/A | 24 | N/A |
| 3/31/2017 | 170 | -13 | N/A | 10 | N/A |
| 12/31/2016 | 167 | -18 | N/A | 2 | N/A |
| 9/30/2016 | 166 | -21 | N/A | 6 | N/A |
| 6/30/2016 | 166 | -34 | N/A | 3 | N/A |
| 3/31/2016 | 164 | -30 | N/A | 20 | N/A |
| 12/31/2015 | 161 | -35 | N/A | 29 | N/A |
| 9/30/2015 | 27 | -47 | N/A | 28 | N/A |
| 6/30/2015 | 60 | -48 | N/A | 22 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: Les bénéfices de CRRX devraient diminuer au cours des 3 prochaines années ( -54.6% par an).
Bénéfices vs marché: Les bénéfices de CRRX devraient diminuer au cours des 3 prochaines années ( -54.6% par an).
Croissance élevée des bénéfices: Les bénéfices de CRRX devraient baisser au cours des trois prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de CRRX ( 4% par an) devrait croître plus lentement que le marché de Canadian ( 4.5% par an).
Croissance élevée des revenus: Le chiffre d'affaires de CRRX ( 4% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CRRX devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/11 03:02 |
| Cours de l'action en fin de journée | 2026/06/11 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
CareRx Corporation est couverte par 11 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Kyle McPhee | ATB Cormark |
| Kyle McPhee | ATB Cormark Historical (Cormark Securities) |
| Doug Cooper | Beacon Securities Limited |